Navigation Links
ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company
Date:7/28/2014

IRVINE, Calif., July 28, 2014 /PRNewswire/ -- ALPHAEON Corporation®, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that it has acquired Physician Recommended Nutriceuticals (PRN)®, a leading developer of specialty omega-3s, and related products for dry eye and macular degeneration, based in Plymouth Meeting, PA, in a transaction worth up to $55M.

"ALPHAEON's acquisition of PRN brings together world renowned ophthalmologists and a premier physician recommended line of nutriceutical products that benefit patients," said CEO Robert E. Grant. "Over the past 5 years, PRN has established a strong leadership position in the rapidly growing field of evidence-based physician recommended and dispensed nutriceuticals, achieving consistently high double-digit growth over several years. We are very pleased to partner with such a quality organization and leadership team and look forward to maintaining their stand-alone operation just outside of Philadelphia, Pennsylvania. This acquisition brings significant customer synergies to both organizations and is ideally aligned to ALPHAEON's mission to provide best-in-class wellness related products to patients."

PRN's dry eye patent pending formula has the highest bioavailable concentration per serving of purified omega-3 fatty acids and the optimal ratio of 3:1 EPA/DHA. Dry Eye Omega Benefits® has been clinically proven to address the inflammation leading to dry eye and improve the recovery time from refractive and cataract surgery. In a dry eye clinical study, 82% of patients who consumed PRN's re-esterified triglyceride (rTG) omega-3 product for an eight-week period had a positive change in the composition of their meibum, a potential root cause of dry-eye syndrome.

PRN CEO Ken Krieg stated, "ALPHAEON's uniquely customer-centric business approach enables physicians to provide world-class products, addressing patient lifestyle and clinical needs. PRN products are created to offer condition-specific solutions while promoting overall patient wellness and are backed by human clinical efficacy studies. This acquisition is well timed to expand the reach of PRN's evidence-based nutriceuticals through ALPHAEON's platform of physician selected services and industry leading marketing campaigns."

Last year, more than 1,200 ophthalmologists in North America recommended PRN's dry eye products and over 100,000 patients have ordered and used PRN products. ALPHAEON will begin offering the omega-3 products to its approximately 1,000 physician customers, participating in ALPHAEON's customer affinity program, commencing on August 1, 2014.

About ALPHAEON Corporation

ALPHAEON Corporation is a lifestyle healthcare company committed to partnering with board-certified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Ensuring access to leading advancements in lifestyle healthcare, the company fosters deep relationships with leading specialty physicians so patients look their best, feel their best and know they are receiving the best in lifestyle healthcare. For more information, please visit www.alphaeon.com

About Strathspey Crown

Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. Strathspey Crown uniquely partners with board certified physician specialists to bring to market highly innovative technologies and services in the self-pay sector. The firm is founded in partnership with physician investors across three key medical specialties: plastic surgery, ophthalmology and dermatology. For more information visit www.strathspeycrown.com.

About Physician Recommended Nutriceuticals

PRN is a leading developer of condition-specific omega-3 products and nutritional supplements. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity. Acknowledged on the Inc. 500|5000 list of fastest growing privately held companies for the third consecutive year, PRN has demonstrated three-year revenue growth of 375%.

PRESS CONTACT:

Jenna Mons, Vice President of Marketing and Communications
Tel: 949-284-4523
Email: press@alphaeon.com  

David Krieg, Director of Communications
Tel: 610-276-1954
Email: dkrieg@prnomegahealth.com   

ALPHAEON® is a registered trademark of ALPHAEON
PRN® is a registered trademark of Physician Recommended Nutriceuticals  
Omega Benefits® is a registered trademark of Physician Recommended Nutriceuticals 

Logo - http://photos.prnewswire.com/prnh/20140728/130500


'/>"/>
SOURCE ALPHAEON Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration
2. ACON Investments Acquires Injured Workers Pharmacy
3. Chiltern acquires Ockham and the companies merge operations
4. Cantel Medical Acquires Sterilator Company, Inc.
5. Data Sciences International acquires Buxco Research Company to expand preclinical research solutions offering
6. BD Acquires Alverix, Inc.
7. Numotion Acquires Specialty Wheelchairs, LLC
8. Aratana Therapeutics Acquires Okapi Sciences NV
9. 180 Medical Acquires Symbius Medical
10. ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals
11. PTS, Inc. Acquires A1CNow and Expands Product Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new patients ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients can ... more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored ... 2.0 — the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. ... telemedicine to improve the lives of the poor and underserved in other parts of ...
(Date:4/24/2017)... ... ... Bright Pink , a national non-profit organization focusing on the prevention and early detection of ... is proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder ... of the Board and launched a national search to find a visionary new leader to ...
Breaking Medicine News(10 mins):